Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study

Gaitanidis, Apostolos; Alevizakos, Michail; Tsaroucha, Alexandra; Pitiakoudis, Michail

doi:10.1007/s12029-018-0137-9

Cited by 3 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible explanations may be the following. First, during the imatinib eras, adjuvant imatinib combined with surgery as the initial treatments could significantly improve the efficacy and survival benefit of GIST 13 17. Next, a stage shift from regional stage to localized stage may contribute to a better long-term survival.…”

Section: Discussionmentioning

confidence: 99%

“…The probable reason could be the high efficacy of imatinib in terms of survival for metastatic or advanced GIST 26 27. Be that as it may, resection of primary tumour could significantly improve the survival of metastatic GIST patients,11 17 28–32 especially combined with target therapy. Even for part of highly select unresectable GIST, receiving cytoreductive surgery combined with target therapy could benefit for survival 33.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Update of epidemiology, survival and initial treatment in patients with gastrointestinal stromal tumour in the USA: a retrospective study based on SEER database

Zhu

Yang²,

Ma³

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesAn updated epidemiological analysis of gastrointestinal stromal tumour (GIST), the change of cancer-specific survival (CSS) and patterns of initial treatment are of interest.DesignA retrospective study using data from the Surveillance, Epidemiology and End Results (SEER) database.Setting and participantsA total of 5625 patients with GIST diagnosed between 2010 and 2019 were identified.Primary outcome measuresAge-standardised incidence rate (ASIR) and annual prevalence rate were calculated. SEER combined stage, period CSS rate and initial treatment were summarised. All the data were calculated by SEER*Stat software.ResultsFrom 2010 to 2019, the ASIR of GIST increased from 0.79 to 1.02 per 100 000 person-years, with an increase of 2.4% annually. The increase was across age and sex subgroups. The prevalence trend was similar with the ASIR trend in each subgroup. The stage distributions were similar between different age groups, but varied among different primary tumour sites. More importantly, a stage shift from regional stage to localized stage at diagnosis was found, which may result in the improvement of CSS over years. Overall, the 5-year CSS rate of GIST was approximately 81.3%. Even for metastatic GIST, the rate exceeded 50%. Surgery was the most common treatment regimen for GIST, followed by surgery and systemic treatment. Whereas approximately 7.0% patients were undertreated, which was more pronounced among patients with distant and unknown stages.ConclusionsThe findings of this study suggest an improving early detection of GIST and an improving ability of accurate staging. Though most patients are effectively treated and perform good survivals, approximate 7.0% patients may be undertreated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Update of epidemiology, survival and initial treatment in patients with gastrointestinal stromal tumour in the USA: a retrospective study based on SEER database

Zhu

Yang²,

Ma³

et al. 2023

BMJ Open

View full text Add to dashboard Cite

show abstract

“…While the prognosis for most GISTs patients following surgery is excellent, tumor recurrence is a typical occurrence in GISTs patients 3 . Regarding the postoperative survival progression of GISTs originating in the stomach and small intestine, some studies 4 , 5 reveal no difference, while a recent study 6 suggests a difference, therefore there is no conclusive consensus. Thus, postoperative determination of survival progression in patients with gastric GISTs remains clinically significant.…”

Section: Introductionmentioning

confidence: 98%

Evaluating nomogram models for predicting survival outcomes in gastric gastrointestinal stromal tumors with SEER database analysis

Yong,

Li,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) predominantly develop in the stomach. While nomogram offer tremendous therapeutic promise, there is yet no ideal nomogram comparison customized specifically for handling categorical data and model selection related gastric GISTs. (1) We selected 5463 patients with gastric GISTs from the SEER Research Plus database spanning from 2000 to 2020; (2) We proposed an advanced missing data imputation algorithm specifically designed for categorical variables; (3) We constructed five Cox nomogram models, each employing distinct methods for the selection and modeling of categorical variables, including Cox (Two-Stage), Lasso-Cox, Ridge-Cox, Elastic Net-Cox, and Cox With Lasso; (4) We conducted a comprehensive comparison of both overall survival (OS) and cancer-specific survival (CSS) tasks at six different time points; (5) To ensure robustness, we performed 50 randomized splits for each task, maintaining a 7:3 ratio between the training and test cohorts with no discernible statistical differences. Among the five models, the Cox (Two-Stage) nomogram contains the fewest features. Notably, at Near-term, Mid-term, and Long-term intervals, the Cox (Two-Stage) model attains the highest Area Under the Curve (AUC), top-1 ratio, and top-3 ratio in both OS and CSS tasks. For the prediction of survival in patients with gastric GISTs, the Cox (Two-Stage) nomogram stands as a simple, stable, and accurate predictive model with substantial promise for clinical application. To enhance the clinical utility and accessibility of our findings, we have deployed the nomogram model online, allowing healthcare professionals and researchers worldwide to access and utilize this predictive tool.

show abstract

Clinical Value of Endoscopic Ultrasonography and Image Analysis Techniques in Assessing the Risk Grade of Gastric Stromal Tumors

杨¹

2022

ACM

View full text Add to dashboard Cite

Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study

Abstract: Surgery for gastric metastatic GISTs is associated with improved survival. No discernible benefit after surgical resection was identified for patients with small intestinal, colorectal, retroperitoneal, or peritoneal metastatic GISTs.

Cited by 3 publications

References 40 publications

Update of epidemiology, survival and initial treatment in patients with gastrointestinal stromal tumour in the USA: a retrospective study based on SEER database

Update of epidemiology, survival and initial treatment in patients with gastrointestinal stromal tumour in the USA: a retrospective study based on SEER database

Evaluating nomogram models for predicting survival outcomes in gastric gastrointestinal stromal tumors with SEER database analysis

Clinical Value of Endoscopic Ultrasonography and Image Analysis Techniques in Assessing the Risk Grade of Gastric Stromal Tumors

Contact Info

Product

Resources

About